This year, the Standards of Care include some major updates that further encourage the use of time in range: The Standards of Care now state (7.16) that in addition to those on insulin, CGM should be considered in adults with type 2 diabetes treated with glucose-lowering medications other than insulin to achieve and maintain individualized glycemic goals
Although rare, serious side effects have been noted, with gallbladder disease and pancreatitis among the most concerning
Source: Evaluate Pharma, World Obesity Federation, Putnam Analysis Q2, 2025 Unmet Needs and Potential Differentiation Levers Despite extraordinary promise, there are still unmet needs that biopharma companies can target to address: GI Tolerability The most common GI adverse events (nausea, vomiting, and diarrhea) often lead to therapy discontinuation
Its value lies primarily in its ability to highlight new possibilities for modulating regeneration and cellular protection
For instance, epinephrine comes in an automated injector form called an EpiPen, which is used to treat anaphylaxis quickly
